Central Nervous System Therapeutics Market To Reach $254.6 Million By 2030

Central Nervous System Therapeutic Market Growth & Trends

The global central nervous system therapeutics market size is expected to reach USD 254.6 million by 2030, registering a CAGR of 10.4% from 2025 to 2030, according to a new report by Grand View Research, Inc. High unmet medical needs and government initiatives to reduce the disease burden are driving the market for central nervous system (CNS) therapeutic over the forecast period. According to WHO, the global economy loses due to depression and anxiety is more than USD 1 trillion per year and rising patient base of mental health globally is expected to increase the economy loses by USD 16 trillion in 2030.

The market holds strong future growth opportunities and major players are adopting different marketing strategies such as new product development, collaborations, geographic expansion, mergers and acquisitions, and new product approval, to strengthen their positions. In February 2020, Biogen announced the investment in Sangamo’s zinc finger platform to develop therapies for Alzheimer’s disease and other neurological diseases. Similarly, the company has an agreement with Ionis Pharmaceutical for the development of drug candidates applicable across a wide range of neurological diseases.

Presence of strong pipeline products by major pharmaceutical companies such as Biogen, H. Lundbeck A/S, Eli Lilly and Company, and others are expected to accelerate market growth over the forecast period. Besides, other pharmaceutical companies are also actively involved in the development of novel therapies and investing heavily to develop effective therapeutics for the treatment of CNS associated diseases.

Most of the late phase development drugs are for the treatment of neurodegenerative disorders such as Alzheimer’s disease, multiple sclerosis, Parkinson’s disease, and amyotrophic lateral sclerosis. The drug candidates such as aducanumab, brexpiprozole, evobrutinib, solanezumab are some of the potential drugs that could be commercialized in the next five to eight years for the treatment of various indication of neurodegenerative disorders. Apart from neurodegenerative diseases, migraine, schizophrenia, and epilepsy are the major CNS disease indications that have potential drug candidates in pipeline.

The cancer segment is expected to witness the fastest growth rate over the forecast period. Increasing prevalence, high mortality rate, and rising demand for effective treatment are expected to fuel the growth of the market for CNS therapeutic. According to National Cancer Institute estimates, the number of new cases of CNS cancers was 23,890 whereas the number of deaths was 18,020 in the U.S. in 2020.

Pharmaceutical companies are adopting strategies such as product development, merger and acquisition, and collaboration to strengthen their position in market. For instance, Biogen has signed agreements with Ionis Pharmaceuticals, Atalanta Therapeutics, and Sangamo Therapeutics to develop novel therapeutics for the treatment of different disease indications of the central nervous system. Similarly, in January 2020, the CNS Pharmaceuticals has entered into a licensing agreement with MD Anderson Cancer Center to investigate WP1244, a designed DNA-binding agent to cross the blood-brain barriers for the potential treatment of brain cancers.

 Request a free sample copy or view report summary: Central Nervous System Therapeutic Market Report

Central Nervous System Therapeutic Market Report Highlights

• Neurodegenerative diseases are projected to witness the fastest growth with a CAGR of 11.5% over the forecast period, owing to the increasing prevalence of conditions such as Alzheimer’s, Parkinson’s, and multiple sclerosis.

• The CNS cancer segment is expected to witness the fastest growth rate over the forecast period. Increasing demand for effective treatment is expected to drive the segment

• In Asia Pacific, the market is estimated to witness the fastest growth over the coming years owing to the increase in treatment rate and betterment of healthcare infrastructure in the region

• North America held a majority of share in 2024 due to high awareness level in the region and better reimbursement scenario  

Central Nervous System Therapeutic Market Segmentation

Grand View Research has segmented the global central nervous system therapeutics market based on disease, drug class, distribution channel, region:

Central Nervous System Therapeutics Disease Outlook (Revenue, USD Million, 2018 - 2030)

• Neurovascular Diseases

• CNS Trauma

• Mental Health

  • Anxiety Disorders

  • Epilepsy

  • Mood Disorders

  • Psychotic Disorders

  • Others

• Neurodegenerative Diseases

  • Alzheimer’s Disease

  • Parkinsosn’s Disease

  • Multiple Sclerosis

  • Huntington’s Disease

  • Amytrophic Lateral Sclerosis

  • Others

• Infectious Diseases

• CNS Cancer

• Others

Central Nervous System Therapeutics Drug Class Outlook (Revenue, USD Million, 2018 - 2030)

• Anesthetics

• Anticonvulsants

• Antiemetics

• CNS Stimulants

• Pain Relievers

• Others

Central Nervous System Therapeutics Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)

• Hospital Pharmacies

• Retail Pharmacies

• Others

Central Nervous System Therapeutics Regional Outlook (Revenue, USD Billion, 2018 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East & Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in the Central Nervous System Therapeutics Market

• Biogen

• Otsuka Pharmaceutical Co., Ltd.

• Eli Lilly and Company

• Merck & Co., Inc.

• Astra Zeneca

• Takeda Pharmaceutical Company Limited

• Novartis AG

• Teva Pharmaceutical Industries Ltd

• Johnson & Johnson Services, Inc.

• Pfizer Inc.